2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline succinic acid | |
---|---|
Trade Name | |
Orphan Indication | Huntington disease |
EU Market Approval | EU |
EU Designation Date | 2016-07-14 00:00:00 |
Sponsor | Pfizer Limited |
Related Access Program